Cargando…

Mutational landscape of chronic myelomonocytic leukemia in Chinese patients

BACKGROUND: Chronic myelomonocytic leukemia (CMML) is a rare and heterogeneous hematological malignancy. It has been shown that the molecular abnormalities such as ASXL1, TET2, SETBP1, and SRSF2 mutations are common in Caucasian population. METHODS: We retrospectively analyzed 178 Chinese CMML patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Nie, Yanbo, Shao, Liang, Zhang, Hong, He, Colin K., Li, Hongyu, Zou, Junyan, Chen, Long, Ji, Huaiyue, Tan, Hao, Lin, Yani, Ru, Kun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128105/
https://www.ncbi.nlm.nih.gov/pubmed/35610628
http://dx.doi.org/10.1186/s40164-022-00284-z
_version_ 1784712492243484672
author Nie, Yanbo
Shao, Liang
Zhang, Hong
He, Colin K.
Li, Hongyu
Zou, Junyan
Chen, Long
Ji, Huaiyue
Tan, Hao
Lin, Yani
Ru, Kun
author_facet Nie, Yanbo
Shao, Liang
Zhang, Hong
He, Colin K.
Li, Hongyu
Zou, Junyan
Chen, Long
Ji, Huaiyue
Tan, Hao
Lin, Yani
Ru, Kun
author_sort Nie, Yanbo
collection PubMed
description BACKGROUND: Chronic myelomonocytic leukemia (CMML) is a rare and heterogeneous hematological malignancy. It has been shown that the molecular abnormalities such as ASXL1, TET2, SETBP1, and SRSF2 mutations are common in Caucasian population. METHODS: We retrospectively analyzed 178 Chinese CMML patients. The targeted next generation sequencing (NGS) was used to evaluate 114 gene variations, and the prognostic factors for OS were determined by COX regression analysis. RESULTS: The CMML patients showed a unique mutational spectrum, including TET2 (36.5%), NRAS (31.5%), ASXL1 (28.7%), SRSF2 (24.7%), and RUNX1 (21.9%). Of the 102 patients with clonal analysis, the ancestral events preferentially occurred in TET2 (18.5%), splicing factors (16.5%), RAS (14.0%), and ASXL1 (7.8%), and the subclonal genes were mainly ASXL1, TET2, and RAS. In addition, the secondary acute myeloid leukemia (sAML) transformed from CMML often had mutations in DNMT3A, ETV6, FLT3, and NPM1, while the primary AML (pAML) demonstrated more mutations in CEBPA, DNMT3A, FLT3, IDH1/2, NPM1, and WT1. It was of note that a series of clones were emerged during the progression from CMML to AML, including DNMT3A, FLT3, and NPM1. By univariate analysis, ASXL1 mutation, intermediate- and high-risk cytogenetic abnormality, CMML-specific prognostic scoring system (CPSS) stratifications (intermediate-2 and high group), and treatment options (best supportive care) predicted for worse OS. Multivariate analysis revealed a similar outcome. CONCLUSIONS: The common mutations in Chinese CMML patients included epigenetic modifiers (TET2 and ASXL1), signaling transduction pathway components (NRAS), and splicing factor (SRSF2). The CMML patients with DNMT3A, ETV6, FLT3, and NPM1 mutations tended to progress to sAML. ASXL1 mutation and therapeutic modalities were independent prognostic factors for CMML. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40164-022-00284-z.
format Online
Article
Text
id pubmed-9128105
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-91281052022-05-25 Mutational landscape of chronic myelomonocytic leukemia in Chinese patients Nie, Yanbo Shao, Liang Zhang, Hong He, Colin K. Li, Hongyu Zou, Junyan Chen, Long Ji, Huaiyue Tan, Hao Lin, Yani Ru, Kun Exp Hematol Oncol Research BACKGROUND: Chronic myelomonocytic leukemia (CMML) is a rare and heterogeneous hematological malignancy. It has been shown that the molecular abnormalities such as ASXL1, TET2, SETBP1, and SRSF2 mutations are common in Caucasian population. METHODS: We retrospectively analyzed 178 Chinese CMML patients. The targeted next generation sequencing (NGS) was used to evaluate 114 gene variations, and the prognostic factors for OS were determined by COX regression analysis. RESULTS: The CMML patients showed a unique mutational spectrum, including TET2 (36.5%), NRAS (31.5%), ASXL1 (28.7%), SRSF2 (24.7%), and RUNX1 (21.9%). Of the 102 patients with clonal analysis, the ancestral events preferentially occurred in TET2 (18.5%), splicing factors (16.5%), RAS (14.0%), and ASXL1 (7.8%), and the subclonal genes were mainly ASXL1, TET2, and RAS. In addition, the secondary acute myeloid leukemia (sAML) transformed from CMML often had mutations in DNMT3A, ETV6, FLT3, and NPM1, while the primary AML (pAML) demonstrated more mutations in CEBPA, DNMT3A, FLT3, IDH1/2, NPM1, and WT1. It was of note that a series of clones were emerged during the progression from CMML to AML, including DNMT3A, FLT3, and NPM1. By univariate analysis, ASXL1 mutation, intermediate- and high-risk cytogenetic abnormality, CMML-specific prognostic scoring system (CPSS) stratifications (intermediate-2 and high group), and treatment options (best supportive care) predicted for worse OS. Multivariate analysis revealed a similar outcome. CONCLUSIONS: The common mutations in Chinese CMML patients included epigenetic modifiers (TET2 and ASXL1), signaling transduction pathway components (NRAS), and splicing factor (SRSF2). The CMML patients with DNMT3A, ETV6, FLT3, and NPM1 mutations tended to progress to sAML. ASXL1 mutation and therapeutic modalities were independent prognostic factors for CMML. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40164-022-00284-z. BioMed Central 2022-05-24 /pmc/articles/PMC9128105/ /pubmed/35610628 http://dx.doi.org/10.1186/s40164-022-00284-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Nie, Yanbo
Shao, Liang
Zhang, Hong
He, Colin K.
Li, Hongyu
Zou, Junyan
Chen, Long
Ji, Huaiyue
Tan, Hao
Lin, Yani
Ru, Kun
Mutational landscape of chronic myelomonocytic leukemia in Chinese patients
title Mutational landscape of chronic myelomonocytic leukemia in Chinese patients
title_full Mutational landscape of chronic myelomonocytic leukemia in Chinese patients
title_fullStr Mutational landscape of chronic myelomonocytic leukemia in Chinese patients
title_full_unstemmed Mutational landscape of chronic myelomonocytic leukemia in Chinese patients
title_short Mutational landscape of chronic myelomonocytic leukemia in Chinese patients
title_sort mutational landscape of chronic myelomonocytic leukemia in chinese patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128105/
https://www.ncbi.nlm.nih.gov/pubmed/35610628
http://dx.doi.org/10.1186/s40164-022-00284-z
work_keys_str_mv AT nieyanbo mutationallandscapeofchronicmyelomonocyticleukemiainchinesepatients
AT shaoliang mutationallandscapeofchronicmyelomonocyticleukemiainchinesepatients
AT zhanghong mutationallandscapeofchronicmyelomonocyticleukemiainchinesepatients
AT hecolink mutationallandscapeofchronicmyelomonocyticleukemiainchinesepatients
AT lihongyu mutationallandscapeofchronicmyelomonocyticleukemiainchinesepatients
AT zoujunyan mutationallandscapeofchronicmyelomonocyticleukemiainchinesepatients
AT chenlong mutationallandscapeofchronicmyelomonocyticleukemiainchinesepatients
AT jihuaiyue mutationallandscapeofchronicmyelomonocyticleukemiainchinesepatients
AT tanhao mutationallandscapeofchronicmyelomonocyticleukemiainchinesepatients
AT linyani mutationallandscapeofchronicmyelomonocyticleukemiainchinesepatients
AT rukun mutationallandscapeofchronicmyelomonocyticleukemiainchinesepatients